New drug Y-3 tested in healthy people for first time in the U.S.
NCT ID NCT06770491
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single dose of the experimental drug Y-3 in 20 healthy adults to see if it is safe and how the body processes it. Participants received either 40 mg, 60 mg, or a placebo. The study is complete and focused on gathering basic safety and drug-level information, not on treating any illness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Y-3
- What could go wrong
- This is a very early Phase 1 study with only 20 healthy people. It is designed to check safety and how the drug moves through the body, not to treat any disease. There is no guarantee Y-3 will ever be tested in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETIC STUDY IN HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tranquil Clinical Research
Webster, Texas, 77598, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a two-drug combo better tame prostate trouble?
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- Tiny study checks if novel bacterium is safe for people
- New painkiller oliceridine tested against morphine in back surgery patients
- New online guide aids dementia caregivers in tough gun safety choices
- New supplement shows promise for stress and sleep in healthy adults